secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001171843-24-003129
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics CEO Vered Bisker-Leib resigns; Thomas Schuetz appointed CEO
--------------------------------------------------------------------------------

- Vered Bisker-Leib, PhD, MBA resigned as CEO and board member effective May 28, 2024, not due to any disagreement.
- Thomas Schuetz, MD, PhD (President of R&D, Vice Chair) appointed President and CEO, and Principal Executive/Financial/Accounting Officer.
- Separation agreement: 18 months base salary, up to 18 months COBRA reimbursement, release of claims.
- Consulting agreement: 15 months at $45,000 annual fee; outstanding equity continues vesting during consultancy.
- Schuetz previously served as CEO; returns to role; Board of Directors reduced to seven members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/0001171843-24-003129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/f8k_052824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-003129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer